| 21.68 1.98 (10.05%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.32 |
1-year : | 29.57 |
| Resists | First : | 21.68 |
Second : | 25.32 |
| Pivot price | 19.36 |
|||
| Supports | First : | 19.8 |
Second : | 18.64 |
| MAs | MA(5) : | 19.63 |
MA(20) : | 19.33 |
| MA(100) : | 18.65 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 71.4 |
D(3) : | 44.6 |
| RSI | RSI(14): 71.9 |
|||
| 52-week | High : | 23.07 | Low : | 14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OCS ] has closed Bollinger Bands are 18.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.71 - 21.8 | 21.8 - 21.89 |
| Low: | 19.61 - 19.69 | 19.69 - 19.78 |
| Close: | 21.53 - 21.69 | 21.69 - 21.85 |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Sat, 06 Dec 2025
Oculis (NASDAQ:OCS) Trading 7% Higher - Here's What Happened - MarketBeat
Sat, 06 Dec 2025
Assessing Oculis Holding (NasdaqGM:OCS) Valuation Following $9.4 Million Shelf Registration Completion - simplywall.st
Sat, 06 Dec 2025
Oculis (Nasdaq: OCS) accelerates Privosegtor into registrational optic neuropathy trials - Stock Titan
Wed, 03 Dec 2025
LifeSci Capital Initiates Coverage of Oculis Holding (OCS) with Outperform Recommendation - Nasdaq
Wed, 03 Dec 2025
Oculis Holding AG (OCS) Upgraded to Buy: Here's What You Should Know - sharewise.com
Wed, 03 Dec 2025
Oculis (NASDAQ: OCS) discloses RSU vesting and settlement by company director - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 3.994e+007 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 65 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.779e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 352.2 % |
| Return on Equity (ttm) | -33.4 % |
| Qtrly Rev. Growth | 791000 % |
| Gross Profit (p.s.) | 89.28 |
| Sales Per Share | -658.5 |
| EBITDA (p.s.) | -3.91214e+008 |
| Qtrly Earnings Growth | -2.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 1.21 |
| Dividend | 0 |
| Forward Dividend | 37250 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|